Posology: The usual posology is one tablet once daily.
The fixed dose combination is not suitable for initial therapy.
If a change of posology is required, titration should be done with the individual components.
Co-administration with other medicines (see Precautions and Interactions): In patients taking hepatitis C antiviral agents elbasvir/grazoprevir or letermovir for cytomegalovirus infection prophylaxis concomitantly with Triveram the dose of atorvastatin in Triveram should not exceed 20 mg/day.
Use of Triveram is not recommended in patients taking letermovir co-administered with ciclosporin.
Renal impairment (see Precautions): Triveram can be administered in patients with creatinine clearance ≥ 60mL/min, and is not suitable for patients with creatinine clearance < 60mL/min. In these patients, an individual dose titration with the monocomponents is recommended.
Elderly (see Precautions and Pharmacology: Pharmacokinetics under Actions): Elderly can be treated with Triveram according to the renal function.
Hepatic impairment (see Contraindications, Precautions and Pharmacology: Pharmacokinetics under Actions): Triveram should be used with caution in patients with hepatic impairment. Triveram is contraindicated in patients with active liver disease.
Paediatric population: The safety and efficacy of Triveram in children and adolescents have not been established. No data are available. Therefore, use in children and adolescents is not recommended.
Method of administration: Oral use.
Triveram tablet should be taken as a single dose once daily in the morning before a meal.